Endocrine journal最新文献

{"title":"Fibroblast growth factor 21-inducing rare sugars prevent diet-induced obesity in male BL/6 mice.","authors":"Oulan Ghnb Efendi, Sho Matsui, Daisuke Kohno, Satoshi Tsuzuki, Tadahiro Kitamura, Tsutomu Sasaki","doi":"10.1507/endocrj.EJ25-0549","DOIUrl":"10.1507/endocrj.EJ25-0549","url":null,"abstract":"<p><p>The consumption of a high-fat, high-sucrose diet (HFHSD) promotes obesity. Although dietary sugars are obesogenic, they activates a negative feedback mechanism between hepatic fibroblast growth factor 21 (FGF21) and oxytocin neurons in the paraventricular nucleus of the hypothalamus (PVH^Oxt), thereby suppressing sugar appetite. We previously reported that the low-calorie rare sugars d-allulose, d-tagatose, and d-sorbitol induce FGF21, activate PVH^Oxt neurons, and reduce sugar intake. In this study, we evaluated the anti-obesity effects of these rare sugars in male BL/6 mice. The mice were fed with HFHSD, along with ad libitum access to FGF21-inducing rare sugar solutions for 1 month. Body weight, feed intake, fluid intake, and total caloric intake were recorded every 3 days. At the end of the treatment, obesity-associated parameters-including insulin resistance, glucose intolerance, and adiposity-were assessed. Rare sugar supplementation reduced body weight gain and total caloric intake without increasing energy expenditure. These interventions improved obesity-associated phenotypes to varying degrees, suggesting that these rare sugars ameliorated the overall state of diet-induced obesity. In contrast, these sugars did not reverse established obesity or insulin resistance, as prolonged HFHSD feeding desensitized mice to their effects. Therefore, rare sugars appear effective for the prevention, but not the treatment, of diet-induced obesity.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"677-690"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reevaluation of urinary calcium excretion as a criterion for surgery in primary hyperparathyroidism: a study on nephrolithiasis risk.","authors":"Yoko Omi, Yuki Yamanashi, Tomoyoshi Nakai, Juro Yanagida, Yusaku Yoshida, Kiyomi Horiuchi, Takahiro Okamoto","doi":"10.1507/endocrj.EJ25-0472","DOIUrl":"10.1507/endocrj.EJ25-0472","url":null,"abstract":"<p><p>The guideline for primary hyperparathyroidism (PHPT) recommends surgery for female patients with 24-hour urinary calcium levels >250 mg/day and male patients >300 mg/day, due to their risk for nephrolithiasis. The purpose of this study is to validate this criterion. We analyzed data from 595 patients undergoing surgery for PHPT. We investigated whether high urinary calcium excretion is associated with nephrolithiasis in PHPT patients, along with the presence of other factors. Nephrolithiasis was present in 224 patients and absent in 371. The 24-hour urinary calcium levels did not differ significantly between patients with nephrolithiasis and those without nephrolithiasis (p = 0.29). The sensitivity and specificity of the guideline thresholds were 54.9% and 53.8% for female patients and 37.8% and 51.5% for male patients. Receiver operating characteristic curve-derived cutoff values were similar to guideline values, but the areas under the curve were approximately 0.5, indicating poor discriminatory ability. Univariable analysis identified male sex, younger age, high serum creatinine, and elevated 24-hour urinary phosphorus, and creatinine levels were linked to nephrolithiasis (p < 0.001, p < 0.001, p < 0.001, p < 0.001 and p < 0.001, respectively). Multivariable analysis revealed that male sex and younger age were associated with nephrolithiasis (p = 0.034 and p < 0.001, respectively). Surgery reduced urinary calcium and phosphorus in both groups, with patients with nephrolithiasis showing higher post-surgery urinary creatinine. In PHPT, the risk of nephrolithiasis cannot be assessed by measuring the urinary calcium excretion level alone, and it should therefore be evaluated by considering multiple lithogenic factors.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"721-728"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of autonomous cortisol secretion on adrenal venous sampling with and without ACTH stimulation in patients with primary aldosteronism.","authors":"Norio Wada, Arina Miyoshi, Koichi Yamamoto, Miki Kakutani, Mika Tsuiki, Akiyo Tanabe, Takuyuki Katabami, Takashi Yoneda, Katsutoshi Takahashi, Shoichiro Izawa, Hiroki Kobayashi, Kohei Kamemura, Minemori Watanabe, Ryuji Okamoto, Hiromasa Goto, Kouichi Tamura, Mitsuhide Naruse, Kenichi Yokota, Masakatsu Sone","doi":"10.1507/endocrj.EJ25-0049","DOIUrl":"10.1507/endocrj.EJ25-0049","url":null,"abstract":"<p><p>The impact of autonomous cortisol secretion (ACS) on adrenal venous sampling (AVS) in patients with primary aldosteronism (PA) remains uncertain. This study aimed to evaluate the effects of ACS on success and lateralization of AVS. From the Japan Primary Aldosteronism Study-II, 872 PA patients with adrenal nodular lesions on computed tomography (CT) who underwent a 1-mg dexamethasone suppression test (DST) were included. ACS was defined as a post-DST cortisol level ≥1.8 μg/dL. AVS success was assessed using selectivity index (cutoff value 2 without, 5 with ACTH-stimulation), and lateralization was determined using lateralization index (cutoff value 2 without, 4 with ACTH-stimulation). Among 872 patients, 283 (32.4%) had ACS. After ACTH-stimulation, AVS success rate was significantly lower in ACS group than in non-ACS group (84.8% vs. 91.0%, p < 0.01), while no significant difference was observed before ACTH-stimulation. Among 524 patients with successful AVS both before and after ACTH-stimulation, 161 (30.7%) had ACS. The proportion of unilateral results did not differ significantly between ACS and non-ACS groups either with or without ACTH. Concordance between AVS and CT laterality was significantly lower in ACS group only without ACTH-stimulation (44.1% vs. 61.7%, p < 0.01). In patients with post-DST cortisol ≥5 μg/dL, reverse AVS-CT laterality was significantly more frequent than in those with cortisol <1.8 μg/dL both with and without ACTH-stimulation. In conclusion, ACS was associated with a lower AVS success rate with ACTH-stimulation, had no impact on rate of unilateral results, but reduced AVS-CT concordance, especially in patients with higher post-DST cortisol levels.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"637-647"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations among serum soluble T-cadherin levels, serum adiponectin levels, and metabolic risk factors in a Japanese population undergoing medical health checkups.","authors":"Masahito Iioka, Shiro Fukuda, Ryohei Mineo, Tomonori Okita, Keitaro Kawada, Emi Horitani, Yoshinari Obata, Hirofumi Nagao, Yuya Fujishima, Jun Murai, Morihiro Matsuda, Tadashi Nakamura, Tohru Funahashi, Hitoshi Nishizawa, Iichiro Shimomura","doi":"10.1507/endocrj.EJ25-0560","DOIUrl":"10.1507/endocrj.EJ25-0560","url":null,"abstract":"<p><p>Soluble T-cadherin (sT-cad), which is a circulating form of membrane T-cadherin, is present in human serum. We examined the relationships among sT-cad levels, adiponectin (APN) levels, and the number of metabolic risk factors in individuals undergoing medical health checkups. A total of 1,144 Japanese individuals (811 males and 333 females, average age: 56.3 ± 9.9 years in males and 53.7 ± 10.1 years in females) were analyzed. Serum levels of sT-cad and APN were measured by enzyme-linked immunosorbent assay (ELISA). Associations of sT-cad and APN levels with the number of metabolic risk factors (abdominal obesity, diabetes, hypertension, and dyslipidemia) were evaluated. Serum 130-kDa sT-cad levels were significantly lower in males than in females, and were positively correlated with APN levels. Individuals with low APN levels exhibited more metabolic risk factors. Notably, among males with high APN levels, those with low 130-kDa sT-cad levels had a greater number of metabolic risk factors than those with high 130-kDa sT-cad levels. Serum 130-kDa sT-cad levels were significantly correlated with APN levels in individuals undergoing medical health checkups. Even among males with high APN levels, low sT-cad levels were indicative of the presence of more metabolic risk factors.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"649-654"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adipose-derived stem cell exosomes mitigate ferroptosis and enhance osteogenesis via miR-215-5p-mediated ubiquitin-specific protease 1 suppression.","authors":"Caihong Sun, Hongwei Wang, Xiulian Lu, Lei Li, Yining Cui","doi":"10.1507/endocrj.EJ25-0336","DOIUrl":"10.1507/endocrj.EJ25-0336","url":null,"abstract":"<p><p>Osteoporosis (OP) is a metabolic bone disease characterized by impaired bone formation and excessive resorption. Ferroptosis has been implicated in osteoblast dysfunction. Adipose-derived stem cell exosomes (ADSC-exos) have emerged as promising regenerative therapies. This study investigated whether ADSC-exos alleviate ferroptosis and promote osteogenic differentiation by modulating the miR-215-5p/USP1/PTEN/AKT/GSK3β/NRF2 pathway. Human ADSC-exos were evaluated using transmission electron microscopy, nanoparticle tracking analysis, and western blot. Ferroptosis was induced in MG63 cells using ferric ammonium citrate (FAC). Cell viability, lipid peroxidation, and osteogenic differentiation were evaluated using the CCK-8 assay, C11-BODIPY staining, malondialdehyde quantification, ALP staining, and Alizarin Red S staining. The effects of ADSC-exos on PTEN ubiquitination and AKT/GSK3β/NRF2 pathway activation were assessed using western blot, RT-qPCR, and immunoprecipitation. ADSC-exos significantly improved osteoblast viability, reduced lipid peroxidation, and enhanced osteogenic differentiation in FAC-treated MG63 cells. Dual-luciferase reporter assay identified miR-215-5p as a key exosomal cargo that targets USP1. Mechanistically, ADSC-exos downregulated USP1, leading to PTEN ubiquitination and degradation, thereby activating the AKT/GSK3β/NRF2 signaling pathway. USP1 overexpression reversed the protective effects of ADSC-exos, confirming that miR-215-5p-mediated USP1 inhibition plays a crucial role in regulating ferroptosis and osteogenic differentiation. In conclusion, ADSC-exos diminish ferroptosis and enhance osteogenic differentiation by delivering miR-215-5p, which inhibits USP1, promotes PTEN ubiquitination, and activates the AKT/GSK3β/NRF2 pathway. These findings provide new insights into the mechanisms by which ADSC-exos promote bone repair and highlight their potential as an innovative treatment for OP.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"621-635"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenvatinib in radioiodine-refractory differentiated thyroid cancer: a real-world institutional analysis.","authors":"Sueyoshi Moritani, Masao Takenobu, Masakazu Yasunaga, Taihei Fujii, Mako Moritani, Rie Bando, Shoko Oda, Yuki Harada, Hiroya Kitano","doi":"10.1507/endocrj.EJ25-0539","DOIUrl":"10.1507/endocrj.EJ25-0539","url":null,"abstract":"<p><p>Lenvatinib is a standard systemic therapy for radioiodine-refractory differentiated thyroid cancer (RAI-R DTC). Although pivotal trials such as SELECT demonstrated significant efficacy, real-world evidence remains limited, particularly regarding treatment timing and the role of planned drug holidays. We retrospectively analyzed 44 consecutive patients with RAI-R DTC treated with lenvatinib between 2015 and 2024. All patients initiated therapy at 24 mg/day, with dose reductions and treatment interruptions-including planned drug holidays-implemented according to toxicity. Efficacy outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and best tumor shrinkage. A subgroup analysis was conducted in patients with lung metastases. The median PFS was 36.0 months, and the median OS was 76.7 months. ORR was 52.3% and DCR was 95.5%. In the lung metastases-only subgroup (n = 25), outcomes were particularly favorable: PFS 58.1 months, unreached OS, ORR 64.0%, and DCR 100%. Univariate Cox analysis identified performance status, histological subtype, TV-DT, and tumor burden as significant prognostic factors. The most common adverse events were hypertension, proteinuria, fatigue, and palmar-plantar erythrodysesthesia; these were generally manageable with dose adjustments and individualized planned holidays. Clinically meaningful renal dysfunction was rare despite frequent proteinuria. Lenvatinib demonstrated durable efficacy and acceptable tolerability in real-world practice, especially in patients with lung metastases. Early treatment initiation and individualized toxicity management-including planned drug holidays-enabled sustained dose intensity and prolonged disease control. These findings support the clinical utility of personalized adverse event management strategies in routine care for RAI-R DTC.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"587-596"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short- and long-term prognostic analysis of supraclavicular oblique incision versus traditional low-collar incision in thyroidectomy.","authors":"WanZhi Chen, Jichun Yu, Wenhui Yu, Meijun Zhong","doi":"10.1507/endocrj.EJ25-0273","DOIUrl":"10.1507/endocrj.EJ25-0273","url":null,"abstract":"<p><p>Thyroidectomy is the primary treatment for papillary thyroid carcinoma (PTC) and the type of incision has a significant impact on the short- and long-term recovery of patients. This retrospective study included data from 280 patients with PTC who underwent thyroidectomy. Patients were divided into 2 groups according to incision type: traditional low-collar incision thyroidectomy (TLCIT); and supraclavicular oblique incision thyroidectomy (SOIT). Demographic characteristics, clinical features, and postoperative complications were compared between the 2 groups. Generalized estimating equations were used to analyze the effects of the 2 incision types on short-term (postoperative pain, wound swelling, heat sensation, and neck discomfort) and long-term (quality of life, scar score, anxiety, and depression scores) indicators. In terms of short-term recovery, SOIT significantly reduced postoperative pain, wound swelling, sensation of heat, and neck discomfort. Interaction analysis revealed that SOIT had a significant effect on reducing postoperative pain 1 week after surgery and on reducing heat sensation and neck discomfort 1 month after surgery. In terms of long-term effects, SOIT significantly improved Short-Form-36 and EQ-5D quality of life scores, reduced scar scores, and decreased anxiety and depression scores. Interaction analysis further indicated that SOIT significantly reduced scar scores at 3 and 6 months postoperatively, and significantly reduced anxiety scores at 6 months postoperatively. Compared with the traditional low-collar incision, the supraclavicular oblique incision yielded better short- and long-term prognoses in thyroidectomies for patients diagnosed with PTC.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"577-586"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use, efficacy, and safety of desmopressin for congenital nephrogenic diabetes insipidus in children: a nationwide survey.","authors":"Kento Ikegawa, Masanobu Fujimoto, Kohei Aoyama, Hirofumi Nakayama, Takuo Kubota, Keisuke Nagasaki, Setsuko Naganuma, Makoto Ono, Shinji Higuchi, Haruo Mizuno, Susumu Kanzaki, Yoshihiko Morikawa, Masataka Honda, Naoko Amano, Yukihiro Hasegawa","doi":"10.1507/endocrj.EJ25-0431","DOIUrl":"10.1507/endocrj.EJ25-0431","url":null,"abstract":"<p><p>Congenital nephrogenic diabetes insipidus (CNDI) is characterized by resistance of the distal nephrons and collecting ducts to arginine vasopressin (AVP). High doses of 1-deamino-8-D-arginine vasopressin (DDAVP), a V2-receptor-selective agonist, are effective in some cases. The present study aimed to demonstrate the use, efficacy, and safety of DDAVP and the characteristics of patients who responded to this treatment. The present, retrospective, multicentric, observational survey of patients with CNDI receiving DDAVP was based on a previous, nationwide survey conducted by the Japanese Society for Pediatric Endocrinology (JSPE) and collected data on the use (formulation, dosage, and treatment duration), efficacy (change in urine output and height SDS), and safety of DDAVP. In the initial survey, 43 of 123 JSPE council members (35.0%) observed the patients. The secondary survey of 13 patients found DDAVP to be effective in five patients (38.5%), as evidenced by a 12.6-31.6% decrease in urine output. The maximum urine osmolality on a water deprivation test and urine osmolality after vasopressin injection were lower in patients who were unresponsive to DDAVP than in those who were responsive to the drug (106 vs. 206 mOsm/H₂O/kg, 140 vs. 525 mOsm/H₂O/kg). The AVPR2 variants identified in the DDAVP-responsive group were p.Ala37Pro, p.Leu44Phe, p.Arg104Cys, and p.Tyr128Ser. DDAVP was effective against CNDI with residual V2R function. The water deprivation test with vasopressin injection and genetic testing may be useful for predicting responsiveness to DDAVP.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":"73 5","pages":"597-605"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147867140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of semaglutide, a GLP-1 receptor agonist, on food preferences in Japanese subjects with type 2 diabetes and visceral fat accumulation.","authors":"Tomoyuki Hara, Yuya Fujishima, Yu Kimura, Kohei Fujii, Yusuke Kawachi, Hirofumi Nagao, Yoshinari Obata, Shiro Fukuda, Naoko Nagai, Hitoshi Nishizawa, Iichiro Shimomura","doi":"10.1507/endocrj.EJ25-0402","DOIUrl":"10.1507/endocrj.EJ25-0402","url":null,"abstract":"<p><p>Obesity and type 2 diabetes mellitus (T2DM) are growing global health burdens, with dietary patterns, particularly high intake of carbohydrate- and fat-rich foods, contributing to disease progression. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is effective for both lowering blood glucose and reducing weight; however, its effects on food preferences for specific macronutrients remain unclear. In this retrospective observational study, we enrolled 32 obese subjects with T2DM who were hospitalized for glycemic control, including 20 who started semaglutide treatment (the Sema group) and 12 who did not receive GLP-1RA therapy. Eating behaviors were assessed using the Dietary Behavior Questionnaire from the Japan Society for the Study of Obesity (JASSO-DBQ), and food preferences for carbohydrates, fat, protein, and dietary fiber were quantitatively evaluated using the Japan Food Preference Questionnaire (JFPQ). Thirteen subjects in the Sema group and eight in the Non-GLP-1 group completed 6-months of follow-up. The Sema group showed significant decreases in HbA1c levels (-1.1%) and body weight (-5.7 kg), with fat loss exceeding skeletal muscle loss. Significant decreases were observed in eating behavior scores for \"Eating Motives,\" \"Way of Eating,\" and \"Dietary Content.\" Notably, semaglutide significantly reduced preferences for sweet and non-sweet carbohydrates and non-sweet fats, without changing protein or dietary fiber preferences. In particular, significant reductions were observed in preferences for Japanese staple foods (e.g., white rice and udon/soba) and high-fat snacks. The Non-GLP-1 group showed no significant changes in food preferences for any of the nutrient categories. In summary, semaglutide treatment in obese subjects with T2DM facilitated weight loss, in part by altering food preferences, which potentially contributed to its metabolic benefits.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":"73 5","pages":"607-619"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147867170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ventricular fibrillation triggered by recurrent hypoglycemia in a patient with insulinoma associated with MEN1: case report and review of literature.","authors":"Kotaro Doi, Shin Kaneko, Yoshikuni Asami, Amane Yamamoto, Takeshi Kano, Yoshikuni Kawaguchi, Kiyoshi Hasegwa, Masafumi Kaiume, Toshiko Kobori, Maki Takeuchi, Junichiro Sato, Midori Fujisihro, Masaomi Nangaku, Noriko Makita","doi":"10.1507/endocrj.EJ25-0494","DOIUrl":"10.1507/endocrj.EJ25-0494","url":null,"abstract":"<p><p>This report describes the case of a 44-year-old woman without structural heart disease who developed ventricular fibrillation (VF) during preoperative management of multiple pancreatic neuroendocrine tumors (NETs) associated with multiple endocrine neoplasia type 1. She had an insulinoma in the uncinate process and a non-functioning NET in the pancreatic tail. Immediately after intravenous glucose administration for recurrent hypoglycemia, VF occurred. An electrocardiogram obtained immediately before VF onset showed repolarization abnormalities with marked QTc prolongation, terminal T-wave bulging, and U waves. Laboratory testing revealed concomitant mild hypokalemia. No coronary artery disease was detected. The severe repolarization abnormalities improved after resection of the insulinoma. The presumed mechanism was that mild hypokalemia and recurrent hypoglycemia, together with hypoglycemia-induced epinephrine surge and extracellular-to-intracellular potassium shift, synergistically prolonged the action potential duration and induced early afterdepolarizations, which progressed from torsades de pointes to VF. This case highlights that unstable glycemic control in insulinoma can precipitate life-threatening arrhythmias, even in the absence of structural heart disease. Particularly when surgery is delayed, maintaining serum potassium as 4.5-5.0 mmol/L and preventing recurrent hypoglycemia are crucially important. Early recognition and intervention might help reduce arrhythmic risk in such patients.</p>","PeriodicalId":11631,"journal":{"name":"Endocrine journal","volume":" ","pages":"655-663"},"PeriodicalIF":2.5,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}